| IQV |
Report |
Revenue |
BEAT |
pred ~$4.35B vs. cons $4.30B |
MEDIUM |
| IQV |
Report |
Adjusted diluted EPS |
BEAT |
pred ~$3.10 vs. cons $3.02 |
MEDIUM |
| IQV |
Report |
Adjusted EBITDA |
IN-LINE |
pred ~$977M vs. cons $968M |
MEDIUM |
| IQV |
Guide |
FY2026 revenue guidance |
UNCHANGED |
guide ~$17.25B vs. cons $17.28B (FY2026) |
MEDIUM |
| IQV |
Guide |
FY2026 adjusted EBITDA guidance |
UNCHANGED |
guide ~$4.00B vs. cons $4.00B (FY2026) |
MEDIUM |
| IQV |
Guide |
FY2026 adjusted diluted EPS guidance |
LOWER |
guide ~$12.80 vs. cons $12.93 (FY2026) |
MEDIUM |
| IQV |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.8% |
— |
MEDIUM |
| IQV |
Return |
5-day cumulative residual |
+0.5% (FADE) |
A ~$3.10 EPS beat versus $3.02 consensus and ~$4.35B revenue versus $4.30B should support an initial +1.8% residual move, but unchanged ~$17.25B revenue and ~$4.00B EBITDA guidance plus ~$12.80 EPS guidance below $12.93 consensus leave limited out-period estimate upside, driving a fade to roughly +0.5% cumulative residual by day five. |
MEDIUM |